Vanda Pharmaceuticals
VNDA
181 hedge funds and large institutions have $1.18B invested in Vanda Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 69 increasing their positions, 63 reducing their positions, and 23 closing their positions.
44% more capital invested
Capital invested by funds: $819M → $1.18B (+$359M)
15% more call options, than puts
Call options by funds: $2.54M | Put options by funds: $2.2M
10% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 63
0.71% less ownership
Funds ownership: 99.48% → 98.78% (-0.71%)
4% less funds holding
Funds holding: 189 → 181 (-8)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIP
Epoch Investment Partners
New York
|
+$12.3M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$10.6M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$9.5M |
| 4 |
Bank of New York Mellon
New York
|
+$9.08M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$7.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$19.4M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$8.71M |
| 3 |
Millennium Management
New York
|
-$8.25M |
| 4 |
Renaissance Technologies
New York
|
-$6.72M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
201
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$10.8K | -718 | Closed |
|
202
Simplex Trading
Chicago,
Illinois
| – | -$9.54K | -533 | Closed |
|
|
WAP
203
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$4K | -290 | Closed |
|
|
WP
204
WealthShield Partners
Cary,
North Carolina
| – | -$2K | -150 | Closed |
|
VNDA Hedge Fund Activity: Q2 2021 in Review
181 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2021, worth a combined $1.18B — up 44% from $819M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VNDA and 16 opened new positions — a net loss of 7 holders — while 63 trimmed existing stakes and 69 added.
The largest buyer was Epoch Investment Partners, adding an estimated $12.3M. The largest seller was Armistice Capital, cutting an estimated $19.4M.
- 181 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2021, down from 189 in Q1 2021.
- Funds reported $1.18B of Vanda Pharmaceuticals stock for Q2 2021, up 44% quarter-over-quarter.
- 16 funds opened new Vanda Pharmaceuticals positions in Q2 2021 and 23 closed out, a net change of -7 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2021 was Epoch Investment Partners, an estimated $12.3M added.
- The largest Vanda Pharmaceuticals seller in Q2 2021 was Armistice Capital, an estimated $19.4M sold.
Based on aggregated 13F filings for Q2 2021.